345 related articles for article (PubMed ID: 33427007)
1. Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD.
Davis AK; Barrett FS; So S; Gukasyan N; Swift TC; Griffiths RR
J Psychopharmacol; 2021 Apr; 35(4):437-446. PubMed ID: 33427007
[TBL] [Abstract][Full Text] [Related]
2. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
Lyvers M; Meester M
J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
[TBL] [Abstract][Full Text] [Related]
3. The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies.
Stocker K; Hartmann M; Ley L; Becker AM; Holze F; Liechti ME
J Psychopharmacol; 2024 Jan; 38(1):80-100. PubMed ID: 37905369
[TBL] [Abstract][Full Text] [Related]
4. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
[TBL] [Abstract][Full Text] [Related]
5. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
Barrett FS; Johnson MW; Griffiths RR
J Psychopharmacol; 2015 Nov; 29(11):1182-90. PubMed ID: 26442957
[TBL] [Abstract][Full Text] [Related]
6. The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs' effects on psychological flexibility.
Wolff M; Mertens LJ; Walter M; Enge S; Evens R
J Psychopharmacol; 2022 Mar; 36(3):387-408. PubMed ID: 35253518
[TBL] [Abstract][Full Text] [Related]
7. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
[TBL] [Abstract][Full Text] [Related]
8. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
[TBL] [Abstract][Full Text] [Related]
9. Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory.
Roseman L; Haijen E; Idialu-Ikato K; Kaelen M; Watts R; Carhart-Harris R
J Psychopharmacol; 2019 Sep; 33(9):1076-1087. PubMed ID: 31294673
[TBL] [Abstract][Full Text] [Related]
10. Phenomenological assessment of psychedelics induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI).
Dworatzyk K; Jansen T; Schmidt TT
PLoS One; 2022; 17(3):e0264927. PubMed ID: 35294453
[TBL] [Abstract][Full Text] [Related]
11. Alterations of consciousness and mystical-type experiences after acute LSD in humans.
Liechti ME; Dolder PC; Schmid Y
Psychopharmacology (Berl); 2017 May; 234(9-10):1499-1510. PubMed ID: 27714429
[TBL] [Abstract][Full Text] [Related]
12. Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland.
Kangaslampi S; Hausen A; Rauteenmaa T
J Psychoactive Drugs; 2020; 52(4):309-318. PubMed ID: 32511073
[TBL] [Abstract][Full Text] [Related]
13. Serotonergic psychedelics LSD & psilocybin increase the fractal dimension of cortical brain activity in spatial and temporal domains.
Varley TF; Carhart-Harris R; Roseman L; Menon DK; Stamatakis EA
Neuroimage; 2020 Oct; 220():117049. PubMed ID: 32619708
[TBL] [Abstract][Full Text] [Related]
14. Translation and Initial Psychometric Evaluation of Spanish Versions of Three Psychedelic Acute Effects Measures: Mystical, Challenging, and Insight Experiences.
Davis AK; Timmermann C; Ortiz Bernal AM; Lancelotta R; Nayak S; Sepeda ND; Nikolaidis A; Griffiths RR
J Psychoactive Drugs; 2023 Jul; ():1-11. PubMed ID: 37449499
[TBL] [Abstract][Full Text] [Related]
15. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
Johnson MW; Hendricks PS; Barrett FS; Griffiths RR
Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880
[TBL] [Abstract][Full Text] [Related]
16. The use of classic psychedelics among adults: a Danish online survey study.
Søgaard Juul T; Ebbesen Jensen M; Fink-Jensen A
Nord J Psychiatry; 2023 May; 77(4):367-378. PubMed ID: 36173202
[TBL] [Abstract][Full Text] [Related]
17. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.
Griffiths RR; Richards WA; McCann U; Jesse R
Psychopharmacology (Berl); 2006 Aug; 187(3):268-83; discussion 284-92. PubMed ID: 16826400
[TBL] [Abstract][Full Text] [Related]
18. Psychedelics and mental health: a population study.
Krebs TS; Johansen PØ
PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
[TBL] [Abstract][Full Text] [Related]
19. Psilocybin occasioned mystical-type experiences.
James E; Robertshaw TL; Hoskins M; Sessa B
Hum Psychopharmacol; 2020 Sep; 35(5):e2742. PubMed ID: 32573835
[TBL] [Abstract][Full Text] [Related]
20. Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020.
Kopra EI; Ferris JA; Winstock AR; Kuypers KP; Young AH; Rucker JJ
J Psychopharmacol; 2023 Jul; 37(7):733-748. PubMed ID: 36876583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
